Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) pays a quarterly distribution from roughly 100 quality-screened U.S. dividend stocks. The fund holds $71.6 billion in assets at an expense ratio of just 0.06%, and it tracks the Dow Jones U.S. Dividend 100 Index, which requires 10 consecutive years of dividend payments and screens on cash flow to debt, ROE, dividend yield, and dividend growth. That methodology is the first line of defense in the SCHD dividend safety story.
How the fund generates its yield
SCHD’s income comes from ordinary dividends paid by its underlying holdings. The top 10 positions each sit near 4% of assets and together account for roughly 41% of the portfolio. Rebalancing happens annually in March, so current names reflect the December 31, 2025 fact sheet: Bristol-Myers Squibb, Merck, ConocoPhillips, Lockheed Martin, Chevron, Verizon, AbbVie, Cisco, Coca-Cola, and Altria. Six of them drive the safety conversation.
Top holdings under the microscope
AbbVie (NYSE:ABBV | ABBV Price Prediction) sits at 3.99% of the fund. Q1 2026 revenue rose 12% to $15 billion, with Skyrizi up 31% to $4.48 billion. AbbVie raised full-year adjusted EPS guidance to $14.08 to $14.28 and lifted its dividend to $1.73 per quarter, the fifth straight annual raise. Humira erosion is real, and immunology successors are filling the gap. Coverage looks solid.
Coca-Cola (NYSE:KO) is a textbook aristocrat. Operating margin expanded to 35% in Q1 2026, free cash flow jumped 132% to $1.76 billion, and full-year FCF guidance sits near $12.2 billion against a dividend that just stepped up to $0.53 per quarter. This marks the 63rd consecutive annual increase. There is no realistic scenario in which this payout is at risk.
Chevron (NYSE:CVX) pays $1.78 per quarter for a yield near 4.2%. Q1 free cash flow swung negative to -$1.55 billion on working capital timing and derivative mismatches, but full-year 2025 FCF of $16.6 billion and 16 straight quarters of $5 billion-plus in shareholder returns tell the real story. Chevron’s 39-year streak of raises reflects a commitment management is unlikely to break for a cyclical trough.
Lockheed Martin (NYSE:LMT) is the closest call. Q1 free cash flow was -$291 million while dividends paid ran $816 million, and program charges hit F-16, C-130, and CH-53K. Management reaffirmed FY26 FCF of $6.5 billion to $6.8 billion and raised the dividend 5% to $3.45 per quarter, its 23rd straight increase. Full-year coverage remains intact.
Verizon (NYSE:VZ) yields around 6.5% and carries the highest scrutiny. Total debt climbed to $172.5 billion after closing the Frontier deal on January 20, 2026. Even so, 2025 free cash flow of $20.1 billion covered the $11.5 billion dividend 1.75x, and 2026 guidance calls for FCF of $21.5 billion or more. Elevated leverage is a genuine risk if rates spike, but today’s coverage is comfortable.
Merck (NYSE:MRK) posted a GAAP loss of -$1.28 per share in Q1, driven entirely by a $9.0 billion Cidara acquisition charge. KEYTRUDA grew 12% to $8.03 billion, and full-year non-GAAP EPS guidance moved up to $5.04 to $5.16 against a $0.85 quarterly payout. The reported loss is accounting noise, and operational cash generation supports the dividend.
Total return context and the verdict
SCHD has returned 20% year to date and 23% over the past year, with a 10-year gain of 227%. Income durability rests on cash-generating businesses, and the annual rebalance culls names that let dividend growth stall. For conservative investors seeking growth and income, SCHD’s distribution reads as safe. Aggressive income hunters chasing higher yields will prefer options-based funds, and growth-tilted dividend investors can consider peer growth-oriented dividend ETFs that trade current yield for faster payout growth.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks